Global Pricing Pressures and the European Patient: Why “Most Favoured Nation” Rules Concern Us All

Across the global pharmaceutical landscape, a profound shift in pricing mechanisms is reshaping how – and when – new treatments reach European patients. At the center of this shift is the United States’ adoption of Most Favoured Nation (MFN) and international reference pricing benchmarks, which tie domestic public drug reimbursement to the lowest prices paid across comparable OECD nations.

For decades, the global biopharmaceutical model relied heavily on high U.S. margins to cross-subsidize research and development. This has allowed companies to accept lower, heavily negotiated prices in European healthcare systems. With Washington now seeking to curb domestic spending by benchmarking against overseas rates, that fragile equilibrium has collapsed: leaving manufacturers facing intense margin squeezes and triggering defensive commercial strategies worldwide.

For cardiovascular patients and healthcare communities across Europe, the consequences are immediate and concerning. As domestic pricing benchmarks are linked to foreign net prices, manufacturers face structural pressure to protect initial baseline revenues. This dynamic has increasingly incentivized the postponement or deprioritization of European regulatory filings in favor of earlier market entry elsewhere. Instead of simultaneous global launches, companies are prioritizing U.S. commercial returns while leaving European patients in administrative limbo.